Interim Report April-June 2018
“General knowledge and understanding of Oncopeptides and our clinical strategy has greatly increased during the spring”
Summary of Q2
Financial overview April 1 – June 30 2018
- Net sales amounted to 0.0 (0.0) MSEK
- Loss for the period was 143.1 (loss: 67.3) MSEK
- Loss per share, before and after dilution, was 3.27 (loss: 1.69) SEK
- On June 30 cash and cash equivalents amounted to 568.2 (535.1) MSEK
Significant events during the period April 1 to June 30 2018
- First patient started treatment with Ygalo® in the Phase I/II study ANCHOR
- A Clinical Advisory Board consisting of internationally recognized researchers within the field of clinical development of hematology treatments was formed
- Updated interim data with Ygalo® from the ongoing HORIZON – trial (RRMM patients without any remaining treatment options) was presented at the European Hematology Association (EHA) meeting in Stockholm showing an Overall Response Rate (ORR) of 32.1% and a Clinical Benefit Rate (CBR) of 39.3%
Financial overview of the group
| 2018 | 2017 | 2018 | 2017 | 2017 | |
| SEK thousand | Apr-Jun | Apr-Jun | Jan-Jun | Jan-Jun | Jan-Dec |
| Net sales | – | – | – | – | – |
| Operating loss | -143,075 | -67,260 | -205,107 | -129,343 | -247,620 |
| Loss before tax | -143,075 | -67,260 | -205,107 | -129,343 | -247,620 |
| Loss for the period | -143,075 | -67,260 | -205,107 | -129,343 | -247,620 |
| Earnings per share before and after dilution (SEK) | -3.27 | -1.69 | -4.91 | -3.54 | -6.44 |
| Cash flow from operating activities | -96,479 | -72,023 | -130,607 | -139,660 | -271,497 |
| Cash and cash equivalents at the end of the period | 568,212 | 535,069 | 568,212 | 535,069 | 404,050 |
| Research & development costs/operating expenses % | 69% | 74% | 75% | 75% | 80% |
Financial calendar
Interim report Q3: October 26
Year-end report 2018: February 22, 2019
For further information, please contact:
Jakob Lindberg, CEO, Oncopeptides
E-mail: jakob.lindberg@oncopeptides.se
Telephone: +46 (0)8 615 20 40
Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: rein.piir@oncopeptides.se
Cell phone: +46 (0)70 853 72 92
About Oncopeptides
Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. The company focus on the development of the lead product candidate Ygalo®, an alkylating peptide, Peptidase Enhanced Compounds (PEnCs). Ygalo® is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from treatment with Ygalo® compared with established alternative drugs for patients with late-stage multiple myeloma. Ygalo® will potentially provide physicians with a new treatment option for patients suffering from this serious disease.
The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on July 13, 2018, at 08.00 (CET).
Visit www.oncopeptides.se for more information.
Tags: